Literature DB >> 21211492

Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.

Jonathan C Tosh1, Louise J Longworth, Elisabeth George.   

Abstract

OBJECTIVE: To review the selection and use of health-related utility values for economic models included in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
METHOD: A cross-sectional review of reports of economic models submitted to the Technology Appraisals program was undertaken to review the health-related utility data included. Data reviewed included identification and selection of data and the methods used for utility elicitation. The methods used were compared with those from the 2004 Methods Guide issued by NICE.
RESULTS: Appraisals conducted after the implementation of the NICE 2004 Methods Guide were reviewed. After exclusion of documents that did not include a de novo cost-utility analysis, 71 submissions (53 manufacturer submissions, 18 assessment group reports) from 39 appraisals were identified, containing 284 unique utility values. Variation was found in the selection, elicitation, valuation, and use of the utility values. Thirty-nine submissions (55%) took utility values from published studies, of which only 31% were identified through a systematic review. Forty-seven (66%) submissions contained health state descriptions reported by patients, and 55 (77%) submissions applied a valuation set derived from the general population. The EQ-5D was used in 35 (49%) submissions, and mapping to a generic health-related quality of life measure was performed in 19 (27%) submissions.
CONCLUSIONS: Only 56% of submissions to NICE and assessment reports included utility values that met the NICE 2004 reference case. This highlights variation in the methods used to select and incorporate utility values in economic models for NICE Technology Appraisals. Copyright
© 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211492     DOI: 10.1016/j.jval.2010.10.015

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  20 in total

1.  Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.

Authors:  Azin Nahvijou; Hossein Safari; Mahmood Yousefi; Marziyeh Rajabi; Morteza Arab-Zozani; Hosein Ameri
Journal:  Breast Cancer       Date:  2020-07-25       Impact factor: 4.239

2.  A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis.

Authors:  Sarah Acaster; Rodolphe Perard; Deven Chauhan; Andrew J Lloyd
Journal:  BMC Health Serv Res       Date:  2013-09-09       Impact factor: 2.655

3.  Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.

Authors:  Gang Chen; Miguel A Garcia-Gordillo; Daniel Collado-Mateo; Borja Del Pozo-Cruz; José C Adsuar; José Manuel Cordero-Ferrera; José María Abellán-Perpiñán; Fernando Ignacio Sánchez-Martínez
Journal:  Patient       Date:  2018-12       Impact factor: 3.883

4.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 5.  A systematic review of utility values for chemotherapy-related adverse events.

Authors:  Fatiha H Shabaruddin; Li-Chia Chen; Rachel A Elliott; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

6.  Quality of life of patients with hematological malignancies and factors affecting health state utility values.

Authors:  Keiichi Osaki; Shinichiro Morishita; Suzuho Takami; Yuki Sakai; Akiho Kamimura; Atsushi Shindo; Eri Kawata
Journal:  Support Care Cancer       Date:  2022-03-12       Impact factor: 3.603

7.  Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis.

Authors:  Christopher J Sampson; Jonathan C Tosh; Christopher P Cheyne; Deborah Broadbent; Marilyn James
Journal:  Syst Rev       Date:  2015-02-21

8.  Estimation of utility values from visual analog scale measures of health in patients undergoing cardiac surgery.

Authors:  Lars Oddershede; Jan Jesper Andreasen; Lars Ehlers
Journal:  Clinicoecon Outcomes Res       Date:  2014-01-10

9.  Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values.

Authors:  William Dunlop; Itrat Iqbal; Ifty Khan; Mario Ouwens; Louise Heron
Journal:  Clinicoecon Outcomes Res       Date:  2013-10-30

10.  Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study.

Authors:  Maíra Libertad Soligo Takemoto; Nilceia Lopes da Silva; Ana Carolina Padula Ribeiro-Pereira; Arthur Orlando Correa Schilithz; Cibele Suzuki
Journal:  Health Qual Life Outcomes       Date:  2015-08-06       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.